Two post hoc analyses in self-identified black and white patients with 
hypertension evaluated the angiotensin II receptor blocker azilsartan medoxomil 
(AZL-M) and the fixed-dose combination of AZL-M with chlorthalidone (AZL-M/CLD) 
versus the ARB olmesartan (OLM) and the OLM fixed-dose combination with 
hydrochlorothiazide (OLM/HCTZ). One analysis pooled 1,610 patients from two 
6-week randomized controlled trials to compare once daily AZL-M 40 mg, AZL-M 80 
mg, OLM 40 mg, and placebo. The second analysis included 1,020 patients from a 
12-week randomized controlled trial to compare once daily AZL-M/CLD 40/25 mg, 
AZL-M/CLD 80/25 mg, and OLM/HCTZ 40/25 mg. Efficacy end points were 24-hour mean 
ambulatory and clinic systolic and diastolic blood pressure (SPB/DBP) and the 
percentage of patients achieving clinic SBP/DBP targets. Treatment with AZL-M 80 
mg lowered mean clinic SBP by 12.5 mm Hg (p <0.01 vs OLM), treatment with 
AZL-M/CLD 40 mg/25 mg lowered mean ambulatory SBP by 31.0 mm Hg and mean clinic 
SBP by 39.3 mm Hg (both p <0.05 vs OLM/HCTZ), and treatment with AZL-M/CLD 80 
mg/25 mg lowered mean ambulatory SBP by 34.4 mm Hg (p <0.01 vs OLM/HCTZ) and 
mean clinic SBP by 39.2 mm Hg (p <0.05 vs OLM/HCTZ). Target BP goals were 
achieved more frequently with AZL-M versus OLM and with AZL-M/CLD versus 
OLM/HCTZ. In conclusion, in both black and white patients, BP was lowered more 
effectively with AZL-M versus OLM and with AZL-M/CLD versus OLM/HCTZ. The 
AZL-M/CLD 40 mg/25 mg combination resulted in a statistically significant 
reduction in BP in both black and white patients.